TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00823628
Drug: contrast agent (iopromide)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: coronary angiography using the allocated contrast agent
Study: NCT00823628
Drug: contrast agent (iodixanol)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: coronary angiography using the allocated contrast agent
Study: NCT04261166
Drug: A5
Normalized name: A5MP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Cannabis oil (diluted in MCT oil). CBD 0.6 mg, THC 3.1 mg (1 drop)
Study: NCT01692717
Drug: Hydrochlorothiazide + Losartan
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg + 50 mg
Study: NCT01692717
Drug: Hydrochlorothiazide + Losartan + Atorvastatin
Normalized name: hydrochlorothiazide / losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg + 50 mg + 10 mg
Study: NCT03190005
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: no medication, healthy subjects.
Study: NCT04298918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral placebo in combination with trastuzumab emtansine.
Study: NCT03235739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching oral placebo
Study: NCT04319575
Drug: root canal treatment and intracanal medicament
Approvals — FDA: no, EMA: no, PMDA: no
Description: after the access preparation and cleaning and shaping was done in 1st appointment using k files,Mani and protapers,Dentsply then in, chitosan calcium hydroxide paste, or ciprofloxacin metronidazole minocycline paste placed in the canal and kept for 4 weeks.
Study: NCT03006705
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study: NCT03006705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Study: NCT02211729
Drug: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
Study: NCT02211729
Drug: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
Study: NCT00081848
Drug: rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00081848
Drug: rF-CEA(6D)/TRICOM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00081848
Drug: Recombinant Fowlpox-GM-CSF
Normalized name: recombinant human GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00081848
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02847650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03306394
Drug: Trifluridine/Tipiracil hydrochloride (S95005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05995288
Drug: Homeopathic Globule
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic globules were administered after careful anamnesis
Study: NCT03448068
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care
Study: NCT02711449
Drug: 0.9% Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
Study: NCT00825500
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato placebo (0 mg)
Study: NCT02703363
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00621699
Drug: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Study: NCT00621699
Drug: 1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
Study: NCT01528111
Drug: LX7101 (0.125%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 0.125% LX7101
Study: NCT01528111
Drug: LX7101 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive vehicle
Study: NCT03844984
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive normal saline 10 mL
Study: NCT02703363
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02703363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02605187
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 600mg po q6h
Study: NCT02605187
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650mg po q6h
Study: NCT02159729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
Study: NCT00791856
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Study: NCT00791856
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
Study: NCT03535896
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
Study: NCT00875030
Drug: Arsuamoon
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose 50 mg arsuamoon tablet
Study: NCT00834522
Drug: Kytril® 1 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 1 mg, single dose non-fasting
Study: NCT00905346
Drug: Topamax® 25 mg Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topamax® Capsule 2 x 25 mg
Study: NCT01437787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT03703102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00428142
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m2 day 1
Study: NCT01834014
Drug: l-LV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Study: NCT00330382
Drug: Bowman-Birk inhibitor concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT02111161
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of Saline 0.9% (250 ml)
Study: NCT04585464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally as a single dose or once daily
Study: NCT04086823
Drug: RZL-012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection to the submental fat area
Study: NCT04086823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01245582
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT00711620
Drug: Thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Study: NCT02192203
Drug: Diclofenac + Menthol Gel
Normalized name: diclofenac / lidocaine / menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diclofenac, 3% menthol
Study: NCT02192203
Drug: Diclofenac Only Gel
Normalized name: diclofenac Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% diclofenac, 0.09% menthol
Study: NCT03462576
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo versus emricasan in Conatus NASH treatment trial
Study: NCT02556450
Drug: Spironolacton
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Spironolacton 25 mg per day
Study: NCT02092012
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: ıv 50 mg dexketoprofen trometamol after anaesthesia induction
Study: NCT01106170
Drug: Provex CV
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: dietary supplement, 2 capsules per day by mouth
Study: NCT03513731
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection into the facet joint
Study: NCT00442780
Drug: BIIB014
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of BIIB014 per dose, schedule,and duration specified in protocol
Study: NCT00442780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
Study: NCT01826253
Drug: hydroxyethylstarch 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
Study: NCT02973685
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin,leucovorin and 5-FU
Study: NCT02973685
Drug: TACE Drug Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, with or without MMC) followed by polyvinyl alcohol particles (PVA)
Study: NCT01433497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01816997
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
Study: NCT01816997
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
Study: NCT00752297
Drug: Preservative-free Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
Study: NCT00752297
Drug: Mentor Purified Toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
Study: NCT00053417
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 15 weeks
Study: NCT01114048
Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1\~28 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D 1\~4, 15-18 Repeated every 28 days~2. Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1\~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~   * Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration
Study: NCT03848286
Drug: KL-A167 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Study: NCT02494479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill designed to match Purisol tablet
Study: NCT00092729
Drug: etoricoxib (MK0663)
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Study: NCT00092729
Drug: Comparator: placebo (unspecified)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Study: NCT00092729
Drug: Comparator: naproxen sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
Study: NCT03015532
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTX-011 (bupivacaine/meloxicam), via instillation
Study: NCT03015532
Drug: Saline Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo via injection
Study: NCT04134845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose
Study: NCT02184195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Match Olaparib 100mg placebo
Study: NCT02184195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Match Olaparib 150mg placebo
Study: NCT02354222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01708603
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered SC
Study: NCT01232647
Drug: Phylloquinone
Normalized name: Phylloquinone
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg daily of vitamin K1
Study: NCT01232647
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo vitamin K1 and placebo MK4 given daily for 18 months
Study: NCT03430869
Drug: F-18 AV-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
Study: NCT03762369
Drug: Placebo of CKD-351
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day
Study: NCT03762369
Drug: Placebo of CKD-351
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day
Study: NCT03762369
Drug: Placebo of D930
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times a day
Study: NCT02943564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
Study: NCT00869180
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical diclofenac patch applied once daily to area of pain
Study: NCT02308982
Drug: Immunoglobulins, Intravenous (Privigen)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02308982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04133792
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg orally daily for 5 years.
Study: NCT04133792
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg orally daily for 5 years.
Study: NCT00870402
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg per day for 9 months
Study: NCT00870402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet per day for nine months
Study: NCT00787462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
Study: NCT02005419
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
Study: NCT03899649
Drug: SOC
Normalized name: Isocet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care treatment
Study: NCT00993265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
Study: NCT00047099
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00047099
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00869180
Drug: Matching Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
Study: NCT03833479
Drug: TSR-042
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
Study: NCT02473445
Drug: Cysteamine Bitartrate
Normalized name: Cysteamine Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine Bitartrate Delayed-release capsules
Study: NCT03910452
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
Study: NCT02171793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01200810
Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00358488
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01246583
Drug: CP-690,550 Ointment 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CP-690,550 Ointment 1 twice daily for 4 weeks
Study: NCT01246583
Drug: CP-690,550 Ointment 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CP-690,550 Ointment 2 twice daily for 4 weeks
Study: NCT03673670
Drug: RPL554 Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: A PDE3/4 inhibitor
Study: NCT00322283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-marched placebo, once per day, oral administration
Study: NCT03673670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo solution
Study: NCT02569814
Drug: Fimasartan/Amlodipine/Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02569814
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02922374
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
Study: NCT01810185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01439282
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles